Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed CD30+ anaplastic large cell lymphoma (ALCL) or Hodgkin's lymphoma
• * At least 50% of malignant cells must react with HeFi-1
• * HIV positive or HIV negative
• Measurable disease
• No symptomatic CNS disease
• Must have failed or be ineligible for standard chemotherapy regimen
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Not specified
• Life expectancy:
• More than 2 months
• Hematopoietic:
• Not specified
• Hepatic:
• No significant hepatic disease
• Bilirubin no greater than 2 mg/dL
• Renal:
• No significant renal disease
• Creatinine no greater than 3 mg/dL
• Cardiovascular:
• No significant cardiovascular disease
• Pulmonary:
• No significant pulmonary disease
• Other:
• No significant endocrine, rheumatologic, or allergic disease
• No active clinical disease caused by cytomegalovirus (CMV), herpes simplex virus (HSV) I, HSV II, hepatitis B, or tuberculosis
• Not pregnant
• Fertile patients must use effective contraception
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• No prior murine antibody therapy
• Chemotherapy:
• See Disease Characteristics
• Endocrine therapy:
• Not specified
• Radiotherapy:
• At least 4 weeks since prior radiotherapy to measurable disease
• Surgery:
• Not specified
• Other
• At least 4 weeks since prior cytotoxic therapy to measurable disease